v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities:    
Net loss $ (1,982,241) $ (3,036,014)
Stock-based compensation expense included in -    
General and administrative costs 233,618 557,040
Research and development costs
Increase (decrease) in -    
Advances on research and development contract services 78,016 69,002
Prepaid insurance (5,442) (5,426)
Other prepaid expenses (39,824) (39,183)
Accounts payable and accrued expenses (25,354) 136,764
Research and development contract liabilities 132,961 (128,936)
Net cash used in operating activities (1,608,266) (2,446,753)
Cash flows from financing activities:    
Exercise of common stock options 6,281
Net cash provided by financing activities 6,281
Cash:    
Net decrease (1,608,266) (2,440,472)
Balance at beginning of period 4,203,488 5,353,392
Balance at end of period 2,595,222 2,912,920
Supplemental disclosures of cash flow information:    
Interest 11,340 5,809
Income taxes

Source

HTML PDF
ZIP